Philip J. Mease, MD, from Swedish Medical Center, discusses results from the phase 4 SPIRIT-H2H clinical trial that compared the safety and efficacy of ixekizumab—an interleukin-17a monoclonal antibody—with adalimumab—a tumor necrosis factor inhibitor—for psoriatic arthritis.
Philip J. Mease, MD, is director of rheumatology research at Swedish Medical Center in Seattle, Washington, and a clinical professor at the University of Washington School of Medicine in Seattle, Washington.
Reference:
Mease PJ, Smolen JS, Behrens F, et al. Multicentre, randomized, open-label, assessor-blinded, parallel-group head-to-head comparison of the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naive to biologic disease-modifying anti-rheumatic drugs: 24-week results [EULAR abstract LB0005]. Ann Rheum Dis. 2019;78(suppl 2):A261. http://scientific.sparx-ip.net/archiveeular/?searchfor=SPIRIT&view=1&c=a&item=2019LB0005. Accessed September 26, 2019.
Financial Disclosures: Dr Mease has served as a paid consultant to AbbVie, Amgen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Galapagos NV, Gilead Sciences, Janssen Pharmaceuticals, Eli Lilly and Company, Novartis, Pfizer, Sun Pharmaceutical Industries, and UCB. Dr Mease has served as a speaker to AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, Janssen Pharmaceuticals, Eli Lilly and Company, Novartis, Pfizer, and UCB. Dr Mease has received research grants from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen Pharmaceuticals, Eli Lilly and Company, Novartis, Pfizer, Sun Pharmaceutical Industries, and UCB.
